The content on this site is intended for healthcare professionals only
Dr Frédéric Pouliot speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the OSPREY study.
OSPREY is a PII/II study of PSMA-targeted PET/CT imaging in prostate cancer patients.
Dr Pouliot outlines the exciting results, and some more details of the study design.
He explains when these tracers may be in the clinic, the effectiveness, and also at what point of diagnosis they should be used.
Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities
New classification for identifying HR myeloma based on cytogenetic abnormalities
Tele-mentoring: Impact of project ECHO
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Choosing Wisely for young women with breast cancer: Radiotherapy
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Choosing Wisely in radiology Tanzania
Why tumour markers are not recommended as screening tests
